At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Healthcare inflation outpaces CPI due to provider shortages. Find out why income investing ensures steady returns despite ...

The weight of being a Hollywood star can take a toll on a person’s weight.In an industry obsessed with physical appearance, a ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...